A trio of early stage deals unveiled with Johnson & Johnson's Boston Innovation Center demonstrate the pharma's new approach for sourcing external innovation quickly with a broad deal-making tool kit.

Late last month, the pharma announced the official opening of the center along with its first three deals: a partnership with and equity investment in microbiome company Vedanta Biosciences Inc., a seed investment in epigenetics play Rodin Therapeutics Inc. and an academic research alliance.